Filtered By:
Infectious Disease: HIV AIDS
Drug: Truvada
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Toxoplasmosis mimicking CMV chorioretinitis in newly diagnosed PLWH: a case report
CONCLUSIONS: despite progressive developments in the management of PLWH, in this case two different kind of opportunistic infection are found in a late-presenter patient. In particular, two aspects can be highlighted. The first one is that, in the setting of an highly impaired immune system, clinical presentation can be deceptive and more than one opportunistic infection can be observed together in the same patient. The second aspect is that after starting antiretroviral therapy, a rapid improvement of viro-immunologic parameters has been documented, probably leading to an immune reconstitution inflammatory syndrome (IRIS)...
Source: Infezioni in Medicina - September 13, 2023 Category: Infectious Diseases Authors: Francesco Lamanna Rosa Anna Passerotto Andrea Carbone Rebecca Jo Steiner Valentina Iannone Pierluigi Francesco Salvo Arturo Ciccullo Gianmaria Baldin Alberto Borghetti Alex Dusina Source Type: research
Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial
CONCLUSION: The addition of GRT to routine care after first-line virologic failure in Uganda and South Africa did not improve rates of resuppression.PRIMARY FUNDING SOURCE: The President's Emergency Plan for AIDS Relief and the National Institute of Allergy and Infectious Diseases.PMID:34698502 | DOI:10.7326/M21-2229
Source: Annals of Internal Medicine - October 26, 2021 Category: Internal Medicine Authors: Mark J Siedner Mahomed-Yunus S Moosa Suzanne McCluskey Rebecca F Gilbert Selvan Pillay Isaac Aturinda Kevin Ard Winnie Muyindike Nicholas Musinguzi Godfrey Masette Melendhran Pillay Pravikrishnen Moodley Jaysingh Brijkumar Tamlyn Rautenberg Gavin George R Source Type: research
Long-acting injectable form of HIV prevention outperforms daily pill in NIH study
(NIH/National Institute of Allergy and Infectious Diseases) A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by NIH. Findings from the Phase 2b/3 study, called HPTN 083, will be discussed during the 23rd International AIDS Conference (AIDS 2020: Virtual).
Source: EurekAlert! - Infectious and Emerging Diseases - July 7, 2020 Category: Infectious Diseases Source Type: news
Post-exposure prophylaxis guidelines for children and adolescents potentially exposed to HIV
UK guidelines for HIV post-exposure prophylaxis (PEP) in adults have recently been updated. Indications for PEP have been modified and there has been a change in the recommended antiretroviral therapy for adults to a combination of raltegravir with tenofovir and emtricitabine (Truvada). Raltegravir and tenofovir are now available in paediatric formulations and offer improved safety and tolerability over previously recommended ritonavir-boosted lopinavir with zidovudine. This guideline provides recommendations for those caring for children potentially exposed to HIV and other bloodborne viruses in primary care, emergency de...
Source: Archives of Disease in Childhood - December 13, 2016 Category: Pediatrics Authors: Bamford, A., Tudor-Williams, G., Foster, C. Tags: Immunology (including allergy), Drugs: infectious diseases, HIV/AIDS, Adolescent health, Child health, Sexual health Guideline Source Type: research
